866-897-8297

Call Is Confidential & Toll Free

Otezla

Otezla is a novel, orally available small molecule inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE -4). It is indicated in the treatment of active psoriatic arthritis in adults (approved by the FDA in March 2014) and moderate to severe plaque psoriasis (approved by the FDA in September 2014). PDE -4 is a cyclic adenosine monophosphate (cAMP)-specific phosphodiesterase that is predominantly located in inflammatory cells. By inhibiting PDE -4, otezla increases intracellular levels of cAMP and thereby inhibits the production of multiple proinflammatory mediators including PDE -4, TNF -alpha, interleukin-2 (IL-2), interferon-gamma, leukotrienes, and nitric oxide synthase. By targeting a central component of the inflammatory signaling cascade rather than a single inflammatory marker, PDE -4 inhibition may restore the homeostatic balance between pro- and anti-inflammatory signalling.

DEPRESSION AND SUICIDE: Otezla has been associated with increased depression and suicidal behaviour in patients. WEIGHT LOSS: Otezla has been associated with weight decrease in patients.

Imprints


Drug: Otezla
Strength: 30 Mg
Pill Imprint: APR 30
Color: Beige
Shape: Four-sided

View Images & Details

Drug: Otezla
Strength: 10 Mg
Pill Imprint: APR 10
Color: Pink
Shape: Four-sided

View Images & Details

Drug: Otezla
Strength: 20 Mg
Pill Imprint: APR 20
Color: Brown
Shape: Four-sided

View Images & Details
Disclaimer: We strive to ensure that the content on pilladdictions.com is current and factual at the time it was written. However, because new information and discoveries are always becoming available, we are not making any representations or warranties with respect to this content. Please always rely on the guidance of your physician for information about the drugs you are taking and the impacts they may or may not have on your health.

Questions About Prescription Drug Addiction?

(888) 740-2069

Questions About Prescription Drug Addiction?